https://www.taxtmi.com/news?id=45769 Regulatory approval enabled import, sale and distribution of Ivosidenib (Tibsovo ) in India as an oral targeted therapy for patients with IDH1 mutated Acute Myeloid Leukemia and cholangiocarcinoma. The authorization followed a positive Subject Expert Committee recommendation and permits commercial introduction under physician prescription and clinical discretion. The sponsor emphasizes efforts to expand patient access, affordability and collaboration with healthcare stakeholders while noting international approvals that informed the national marketing authorization. en-us Thu, 05 Jun 2025 17:16:03 +0530 Thu, 05 Jun 2025 17:16:03 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=45769 Regulatory approval enabled import, sale and distribution of Ivosidenib (Tibsovo ) in India as an oral targeted therapy for patients with IDH1 mutated Acute Myeloid Leukemia and cholangiocarcinoma. The authorization followed a positive Subject Expert Committee recommendation and permits commercial introduction under physician prescription and clinical discretion. The sponsor emphasizes efforts to expand patient access, affordability and collaboration with healthcare stakeholders while noting international approvals that informed the national marketing authorization. News - Thu, 05 Jun 2025 17:16:03 +0530 https://www.taxtmi.com/news?id=45769